FDA approves Caplyta for major depressive disorder in adults

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...
The American Journal of Managed Care

FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
Fierce Pharma

J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
Medical News Today

Depression vs. seasonal depression: Key differences and finding care

Depression and seasonal affective disorder (SAD) share similar symptoms, but depression can occur at any time of the year, while SAD follows a recurring seasonal pattern. For a SAD diagnosis, a person ...